ClinicalTrials.gg
RecruitingNCT06960759CoughLESSUpdated Aug 18, 2026

Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough

A Phase 2 interventional study of BCS+inactive and BCS+active in Chronic Cough (CC), Refractory Chronic Cough and Unexplained Chronic Cough, sponsored by University of Montana. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by University of Montana · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Chronic Cough with a site in United States — 9 open to participants now, 10 under way, none of them phase 3. Chronic Cough · United States.

Planned enrollment
12th of 37
135 · median 50
Started
2026
with 1 other
Phase 2
16 of 44
3 open now
Registered
42nd of 44
by date
Lead sponsor
5 of 44
University of Montana

Among the 44 studies in Chronic Cough with a site in United States, this one is the 12th largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2026, is one of 16 in phase 2, and was the 42nd registered.

Chronic Cough

142 studies on the registry are indexed under Chronic Cough; 38 are open to participants now.

Browse Chronic Cough studies →

Open to participants now

9 of the 44 studies in Chronic Cough with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 12 (40%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Chronic Cough with a site in United States, or all of them as a file.
02

Study summary

This study is testing new ways to help people who have chronic cough that has not improved with typical treatments. One approach is called behavioral cough suppression (BCS) therapy, which teaches people techniques to stop themselves from coughing. Another approach uses a natural substance thought to help reduce the body's sensitivity to cough triggers.

In this study, we will test two treatments and include one no-treatment control group. The control group will undergo baseline testing, cough monitoring, and an fMRI brain scan and will be offered BCS at end of study participation.

The two treatments include:

  • BCS therapy with active inhaled treatment (BCS+active),
  • BCS therapy with inactive inhaled treatment (BCS+inactive),

The investigators will enroll 135 adults with refractory chronic cough (RCC). 100 participants who qualify and are willing and able to complete 14 study visits in the clinic and two online study visits will be randomly assigned to one of the two treatments. The no-treatment control group (n=35) will be recruited from adults with RCC who are willing to complete baseline testing and fMRI but are not able or willing to attend 14 study clinic visits. These participants will not be randomized.

The investigators want to find out how these treatments affect:

  • How sensitive someone is to things that make them cough,
  • How well they can hold back a cough when they try,
  • How their brain responds to things that cause an urge-to-cough,
  • And how much their coughing affects their quality of life.

The investigators believe both treatments will reduce sensitivity to cough stimulants, reduce cough severity, and improve quality of life, but BCS+active inhaled treatment will work better than BCS+inactive inhaled treatment.

Read the detailed description

Refractory chronic cough (RCC) is a persistent and costly condition that is difficult to treat, often persisting despite appropriate treatment of underlying causes. While behavioral cough suppression (BCS) therapy has shown effectiveness in reducing cough frequency and improving quality of life in controlled studies, it remains underutilized, and the mechanisms by which it works are not well understood.

This multi-site randomized controlled trial will investigate the effects and mechanisms of BCS therapy with and without the addition of an inhaled substance designed to enhance the effect of BCS treatment. The active inhaled substance used in the study has demonstrated desensitization effects on sensory pathways in conditions such as chronic rhinitis and pain syndromes, suggesting potential utility in modulating cough-related neural pathways. Inhalation of this substance has been shown to be safe across multiple studies.

The investigators will recruit 135 participants diagnosed with RCC. 100 participants will be randomized into one of two treatment arms -- BCS combined with an active inhaled substance, and BCS combined with an inactive inhalant. A non-randomized no-treatment control group (n=35) will be included to provide a control comparison to fMRI.

Participants in the treatment arms will undergo 12 treatment sessions over several weeks. The study will evaluate both behavioral and neural markers of treatment response. Primary outcome measures will include:

  • Cough sensory threshold (C5): the lowest concentration of citric acid causing five or more coughs,
  • Cough suppression ability (CS Thresh Diff): the ability to suppress cough when instructed, quantified by the difference between the dose of capsaicin causing five or more coughs when trying to suppress cough (CS5) and C5,
  • Urge-to-cough (UTC) sensory-motor threshold difference (UTC S-M Thresh Diff): a measure of how perception of the need to cough relates to actual coughing behavior,
  • Blood oxygen level dependent (BOLD) neural responses using whole-brain functional MRI (fMRI) during UTC stimulation.

The following patient-report outcome measures (PROMS) will be included as secondary outcomes:

  • Leicester Cough Questionnaire (LCQ): Assesses patient-reported cough-related quality of life, relevant for assessing the broader impact of treatment.
  • PROMIS-Global Health: Assesses patient-reported generalized quality of life, relevant for assessing the broader impact of treatment.
  • Voice Handicap Index-10 (VHI-10): Assesses patient-reported impact of voice problems and is relevant for assessing the broader impact of treatment.
  • Newcastle Laryngeal Hypersensitivity Questionnaire (NLHQ): Assesses patient-reported laryngeal sensory symptoms and is relevant for assessing the broader impact of treatment
  • Multidimensional Assessment of Interoceptive Awareness (MAIA-2): Assesses patient-reported awareness and regulation of bodily sensations and is relevant for assessing the broader impact of treatment
  • Patient Global Impression of Severity (PGI-S): Assesses patient-reported overall perception of cough severity and is relevant for assessing the broader impact of treatment
  • Patient Global of Impression of Change (PGI-C): Assesses patient-reported impression of change related to treatment and is relevant for assessing the broader impact of treatment
  • PROMIS-Sleep: Assesses patient-reported sleep quality and is relevant for assessing the broader impact of treatment

Ambulatory cough frequency monitoring will also be included as a secondary outcome. This data will be collected with the CoughMonitor smartwatch by Hyfe, Inc.

The investigators hypothesize that both treatments will lead to desensitization of cough sensitivity (i.e., increase in C5). We further hypothesize that the combination of BCS+active inhaled treatment will provide the greatest therapeutic benefit on all outcome measures due to simultaneous peripheral desensitization and central sensory-motor modulation. Regarding fMRI, we hypothesize that both treatments will result in increased activity in areas responsible for motor inhibition (e.g., prefrontal cortex).

03

Conditions studied

  • Chronic Cough (CC)
  • Refractory Chronic Cough
  • Unexplained Chronic Cough

Browse trials for

Keywords

  • cough hypersensitivity syndrome
  • randomized control trial
  • neurogenic cough
  • refractory chronic cough
  • unexplained chronic cough
  • chronic cough
  • behavioral cough suppression therapy
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible to participate, participants must meet the following criteria:

  • 18 - 99 years of age
  • Diagnosis of or unexplained chronic cough
  • Normal chest imaging (x-ray or CT scan) within past 2 years, without change in cough symptoms
  • If you a potential participant has asthma, the following criteria must be met:

    • Asthma diagnosed by a pulmonary provider
    • Documentation from a pulmonary provider that asthma is well-controlled
    • Agree to carry prescribed rescue inhaler to each study visit
    • Can tolerate, and agree to, avoid rescue inhaler use for 4 hours prior to each study visit. If rescue inhaler use is unavoidable within 4 hours of a study visit, agree to inform researchers in advance so that the session can be rescheduled.
  • Normal pulmonary function testing with spirometry (/FVC of at least 70% if diagnosed with asthma) within 2 years (6 months for those with a diagnosis of asthma), without change in symptoms since (NOTE: spirometry is included as part of cough threshold testing and can serve as this criteria if the participant has not had spirometry within the designated time.)
  • Laryngoscopy or stroboscopy within 2 years without evidence of structural pathology and no change in vocal quality since exam
  • Proficient reader/speaker of English
  • Willing to take a pregnancy test before enrollment (if applicable)
  • Willing to use during the study (if applicable)
  • Access to reliable internet, working email address (for surveys) and a smart phone (for use with CoughMonitor Watch)
  • Demonstrates understanding in study procedures and risks in order to consent
  • Available, and willing, to comply to all study procedures and clinic visits.

Exclusion criteria

EXCLUSION CRITERIA

Any of the following will be grounds for exclusion from the study:

  • Currently a smoker of any substance or has a positive history of smoking any substance within the last 6 months
  • Currently suffering from any signs of an upper respiratory infection (other than cough)
  • Hemoptysis (coughing up blood) within the last 6 months
  • Pulmonary diagnosis other than asthma
  • Asthma criteria - participant is deemed ineligible if screened for one or more of the following:

    • Use of rescue inhaler in response to active asthma symptoms ≥ 2 times per week
    • Respiratory related emergency department visit within the past 4 weeks
    • Respiratory related ICU admission within the past 12 months
    • Asthma exacerbation requiring systemic use within the past 4 weeks
  • Pregnant or trying to become pregnant
  • Any complaints or clinical symptoms of dysphagia
  • Live with someone with chronic cough or work with someone with chronic cough who is in close proximity (e.g., within 25 feet) on a daily or nearly daily basis
  • Known allergy to peppers
  • Currently receiving or has received BCS therapy for management of chronic cough
  • Excluded concomitant medications:

    • Inhaled pulmonary medications (inhaled corticosteroids, short-acting beta agonists, long-acting beta-agonist, short-acting muscarinic antagonists), unless prescribed for asthma by pulmonary provider: 30 days prior to Visit 1 through completion of study participation
    • ACE inhibitor (benazepril, captopril, enalapril, fosiniopril, lisinopril, perindopril, quinapril, ramipril, trandolapril): 30 days prior to Visit 1 through completion of study participation.
    • Narcotic antitussive (hydrocodone, oxycodone, morphine, codeine, tramadol): 7 days prior to Visit 1 through completion of study participation
    • Non-narcotic antitussive (benzonatate/Tessalon, dextromethorphan/Delsym, carbetapentane/Solotuss): 7 days prior to Visit 1 through completion of study
    • P2X3 receptor antagonist (gefapixant/Lyfnua): 14 days prior to Visit 1 through completion of study
    • Any off-label prescription medication prescribed for cough (pregabalin/Lyrica, gabapentin/Neurontin, amitriptyline/Elavil): 14 days prior to Visit 1 through completion of study *if a neuromodulator is prescribed for something other than cough, participant must be on a stable dose for a minimum of 7 days

The following additional exclusion criteria will apply to participants who will undergo fMRI:

  • Presence of metal implants, devices or fragments (e.g., shrapnel) in the body
  • Claustrophobia
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
135 participants (estimated)

Study arms

  • Active comparator
    Behavioral treatment plus inactive drug

    Participants receive behavioral cough suppression therapy (BCST) combined with an inactive inhaled substance.

    Behavioral: BCS+inactive

  • Experimental
    Behavioral treatment plus inhaled drug

    Participants receive behavioral cough suppression (BCS) therapy combined with inhaled drug designed to enhance BCS therapy

    Combination Product: BCS+active

  • No intervention
    fMRI Control

    Participants will undergo assessments without treatment

Interventions

  • BehavioralBCS+inactive

    Behavioral cough suppression therapy plus inactive inhaled drug. Treatment given twice per week for 12 sessions.

  • Combination productBCS+active

    Behavioral cough suppression therapy combined with inhaled natural substance known to desensitize sensory nerves. Treatment given twice per week for 12 sessions.

06

What researchers measure

Primary outcomes

  1. Cough threshold sensory testing (CTT)

    Measure of cough sensitivity using progressive doses of inhaled vaporized citric acid. The dose causing 5 or more coughs (C5) is the endpoint.

    Time frame: From enrollment to 4 weeks following enrollment

  2. Cough suppression threshold difference (CS Thresh Diff)

    Measure of cough suppression ability. The participant first completes cough suppression threshold testing which involves inhalation of progressive doses of citric acid while actively trying to suppress cough. The dose causing 5 or more coughs when trying to not cough (CS5) is the endpoint. CS Thresh Diff is the difference between CS5 and C5.

    Time frame: From enrollment to 4 weeks following enrollment

  3. Urge-to-Cough Sensory Motor Threshold Difference (UTC S-M Thresh Diff)

    A measure of the relationship between sensation of UTC and motor action of coughing. The measure is determined by calculating the difference between first UTC felt during cough threshold testing (Cu) and UTC at the dose of citric acid that causes 2 or more coughs (C2) (i.e., UTC at C2 - UTC at Cu).

    Time frame: From enrollment to 4 weeks following enrollment

  4. Blood oxygen level dependent neural responses (BOLD)

    Whole-brain fMRI performed during inhalation of capsaicin to trigger urge-to-cough. (NOTE: this measure is only required for those enrolling at Univ. of Colorado)

    Time frame: 4 weeks following enrollment BCS+CAP and BCS+Sham participants; enrollment to 1 week post-enrollment for the fMRI control group

Secondary outcomes

  1. Leicester Cough Questionnaire (LCQ)

    19-item patient-report outcome measure related to the impact of cough on quality of life

    Time frame: From enrollment to 19 weeks following enrollment

  2. Cough frequency

    Ambulatory cough frequency monitoring with a specialized smartwatch, which is worn for 5 days before treatment and 5 days following treatment

    Time frame: From enrollment to 11 weeks following enrollment

  3. Newcastle Laryngeal Hypersensitivity Questionnaire (NLHQ)

    The NLHQ consists of 14 questions assessing laryngeal paresthesia (i.e., abnormal sensory symptoms) commonly seen in RCC. A lower score indicates greater paresthesia.

    Time frame: From enrollment to 19 weeks following enrollment

  4. Voice Handicap Index - 10 (VHI-10)

    The VHI-10 assesses the functional impact of dysphonia on life, which is often seen in patients with RCC. The higher the score, the greater the impact of dysphonia on life.

    Time frame: From enrollment to 19 weeks following enrollment

  5. Multidimensional Assessment of Interoceptive Awareness (MAIA-2)

    The MAIA-2 has 14 questions and is collected via an electronic survey at the Baseline Visit (Visit 1) and Visit 14 (PT1). The primary purpose of MAIA-2 is to assess participants general interoceptive awareness (i.e., awareness of internal bodily sensations). The key domains are noticing, not-distracting, emotional awareness, self-regulation, body listening, and trusting.

    Time frame: From enrollment to 8 weeks following enrollment

  6. PROMIS - Global Health

    The PROMIS - Global Health assesses general, health-related quality of life. This instrument has 10 questions in the key domains of physical health, mental health, social health, pain, and fatigue.

    Time frame: From enrollment to 11 weeks following enrollment

  7. PROMIS - Sleep

    The PROMIS - Sleep questionnaire assesses quality of life relating to sleep. It has 10 questions.

    Time frame: From enrollment to 8 weeks following enrollment

  8. Patient Global Impression of Severity (PGI-S)

    PGI-S is a single, global severity construct that assesses participants overall perception of cough severity. Using the single question of "How would you rate the overall severity of your cough?", participants will rate their perception of cough severity between 0-4 (0 representing "no cough" and 4 representing "very severe".

    Time frame: From enrollment to 19 weeks following enrollment

  9. Patient Global Impression of Change (PGI-C)

    PGI-C is a single, global change construct used to assess participants overall perception of change following a treatment. It will be asked specifically in regard to treatment for chronic cough using the single question of "Since beginning treatment, how would you describe the overall change in your chronic cough?". Participants will rate their perception of change between 1-7 (1 representing "very much improved", 4 representing "no change", and 7 representing "very much worse".

    Time frame: From enrollment to 19 weeks following enrollment

  10. Study Specific Questions (3; 3-SSQ)

    There are three, study specific questions that will be collected as a PROM at Baseline Visit (Visit 1), Visit 8, Visit 14/PT1, PT2, and PT3 to assess frequency of daily uncontrollable coughing, frequency of daily urinary incontinence, and frequency of daily urge-to-cough.

    Time frame: From enrollment to 19 weeks following enrollment

07

Study locations

2 of 3 sites recruiting
08

References and documents

Publications

  • Losche D, Furst W, Falk M, Weickert H. [Preparation of a cytostatic-containing bone cement]. Pharmazie. 1987 Feb;42(2):97-9. German. PubMed 3602068 ↗
  • Moe AAK, Singh N, Dimmock M, Cox K, McGarvey L, Chung KF, McGovern AE, McMahon M, Richards AL, Farrell MJ, Mazzone SB. Brainstem processing of cough sensory inputs in chronic cough hypersensitivity. EBioMedicine. 2024 Feb;100:104976. doi: 10.1016/j.ebiom.2024.104976. Epub 2024 Jan 19. PubMed 38244293 ↗
  • Slovarp LJ, Reynolds JE, Tolbert S, Campbell S, Welby S, Morkrid P. Cough desensitization treatment for patients with refractory chronic cough: results of a second pilot randomized control trial. BMC Pulm Med. 2023 Apr 28;23(1):148. doi: 10.1186/s12890-023-02423-6. PubMed 37118696 ↗
  • Slovarp L, Reynolds JE, Bozarth-Dailey E, Popp S, Campbell S, Morkrid P. Cough desensitization treatment: A randomized, sham-controlled pilot trial for patients with refractory chronic cough. Respir Med. 2022 Mar;193:106739. doi: 10.1016/j.rmed.2022.106739. Epub 2022 Jan 15. PubMed 35091204 ↗
  • Chamberlain SA, Garrod R, Douiri A, Masefield S, Powell P, Bucher C, Pandyan A, Morice AH, Birring SS. The impact of chronic cough: a cross-sectional European survey. Lung. 2015 Jun;193(3):401-8. doi: 10.1007/s00408-015-9701-2. Epub 2015 Mar 19. PubMed 25787221 ↗

Individual participant data

Plan to share: Yes

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jun 2029, 34 months after the start.

Of 25 phase 2 interventional studies under Chronic Cough, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's planned 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 7, 2025
StartActual
Aug 13, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Mar 31, 2030
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06960759
Lead sponsor
University of Montana
Collaborators
University of Colorado, Denver, Emory University, University of Melbourne
Responsible party
Laurie Slovarp (Professor, University of Montana) — Principal investigator
First posted
May 7, 2025
Start date
Aug 13, 2026
Primary completion
Jun 30, 2029 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Aug 18, 2026

Study contacts

Laurie J Slovarp, PhD
Contact
laurie.slovarp@umontana.edu
406-243-2107
Marie Jetté, PhD
Contact
marie.jette@cuanschutz.edu
Laurie J Slovarp, PhD
principal investigator · University of Montana
Marie Jetté, PhD
principal investigator · University of Colorado, Denver
Amanda Gillespie, PhD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion